Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 5
2006 3
2007 1
2008 1
2009 6
2010 4
2011 6
2012 5
2013 7
2014 3
2015 8
2016 3
2017 4
2018 10
2019 5
2020 8
2021 13
2022 10
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies.
Denis M, Grasselly C, Choffour PA, Wierinckx A, Mathé D, Chettab K, Tourette A, Talhi N, Bourguignon A, Birzele F, Kress E, Jordheim LP, Klein C, Matera EL, Dumontet C. Denis M, et al. Among authors: jordheim lp. Cancer Immunol Res. 2022 Aug 3;10(8):1013-1027. doi: 10.1158/2326-6066.CIR-21-0802. Cancer Immunol Res. 2022. PMID: 35679518
Hybrid core-shell particles for mRNA systemic delivery.
Andretto V, Repellin M, Pujol M, Almouazen E, Sidi-Boumedine J, Granjon T, Zhang H, Remaut K, Jordheim LP, Briançon S, Keil IS, Vascotto F, Walzer KC, Sahin U, Haas H, Kryza D, Lollo G. Andretto V, et al. Among authors: jordheim lp. J Control Release. 2023 Jan;353:1037-1049. doi: 10.1016/j.jconrel.2022.11.042. Epub 2022 Dec 22. J Control Release. 2023. PMID: 36442614 Free article.
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, Kryza D, Evesque A, Jordheim LP, Perrial E, Matera EL, Caroff M, Kerzerho J, Dumontet C. Chettab K, et al. Among authors: jordheim lp. Front Immunol. 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402. eCollection 2023. Front Immunol. 2023. PMID: 37223101 Free PMC article.
The druggability of intracellular nucleotide-degrading enzymes.
Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP. Rampazzo C, et al. Among authors: jordheim lp. Cancer Chemother Pharmacol. 2016 May;77(5):883-93. doi: 10.1007/s00280-015-2921-6. Epub 2015 Nov 27. Cancer Chemother Pharmacol. 2016. PMID: 26614508 Review.
The amazing cN-II, the enzyme that keeps us busy.
Jordheim LP. Jordheim LP. Nucleosides Nucleotides Nucleic Acids. 2022;41(3):239-246. doi: 10.1080/15257770.2021.1983828. Epub 2021 Oct 6. Nucleosides Nucleotides Nucleic Acids. 2022. PMID: 34612808 Review.
Regulation of tumor infiltrated innate immune cells by adenosine.
Strakhova R, Cadassou O, Cros-Perrial E, Jordheim LP. Strakhova R, et al. Among authors: jordheim lp. Purinergic Signal. 2020 Sep;16(3):289-295. doi: 10.1007/s11302-020-09701-6. Epub 2020 Jun 12. Purinergic Signal. 2020. PMID: 32529478 Free PMC article. Review.
97 results